Researchers have developed an artificial intelligence (AI) model, called TRTpred, that can accurately predict tumor-killing immune cells. The AI model was trained using gene-expression profiles from 235 T cell receptors (TCRs) of patients with metastatic melanoma. The model was able to accurately identify tumor-reactive T cells with a 90% accuracy rate. The researchers further refined the selection process by applying algorithms to identify T cells with high binding strength to tumor antigens. The combination of TRTpred and the algorithmic filters, known as MixTRTpred, was validated in mice by identifying tumor-reactive T cells capable of eliminating tumors. The researchers believe this AI model has the potential to revolutionize cancer immunotherapies by offering personalized targeting of the most effective tumor-killing T cells.